A protocol of a single arm, prospective, open-label, multicenter, phase II study of ramucirumab and erlotinib in treatment-naïve non-small cell lung cancer patients with EGFR mutation and brain metastases (SPIRAL-BRAIN study)

BACKGROUND: The combination of erlotinib, a first-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and ramucirumab, an anti-vascular endothelial growth factor receptor (VEGFR) antibody, is one of the most effective treatments for patients with non-small cell lung can...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Ryo, Nishioka, Naoya, Kim, Young Hak, Kiyomi, Fumiaki, Uchino, Junji, Takayama, Koichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483078/
https://www.ncbi.nlm.nih.gov/pubmed/37691860
http://dx.doi.org/10.21037/tlcr-23-109

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10483078/
https://www.ncbi.nlm.nih.gov/pubmed/37691860
http://dx.doi.org/10.21037/tlcr-23-109

Ejemplares similares